Results 221 to 230 of about 3,169,653 (411)

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease. [PDF]

Medicina (Kaunas)
Takahashi T, Saito A, Yorozuya T, Nishikiori H, Kuronuma K, Chiba H.   +5 more
europepmc   +1 more source

Photoaffinity labeling of the purified skeletal muscle calcium antagonist receptor by a novel benzothiazepine, [3H]azidobutyryl diltiazem

, 1989
Ken Naito, Edward J. McKenna, Arnold Schwartz, Pál L. Vághy   +3 more
openalex   +1 more source

ESTIMATION OF pK_B VALUES FOR HISTAMINE H₂‐RECEPTOR ANTAGONISTS USING AN in vitro ACID SECRETION ASSAY [PDF]

, 1980
James A. Angus, J.W. Black, M. Stone
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Chronic treatment with adenosine A1 receptor antagonist promotes neurogenesis and improves outcome after cerebral ischemia. [PDF]

J Cereb Blood Flow Metab
Ardaya M, Benito-Muñoz M, Rubio-López E, Garbizu M, Aguado L, Mocha-Muñoz N, Iglesias L, Aldutzin U, Matute C, Soria FN, Gómez-Vallejo V, García-Etxarri A, Llop J, Cavaliere F, Martín A.   +14 more
europepmc   +1 more source

Comparison of levocabastine, a new selective H1‐receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. [PDF]

, 1986
M Kolly, Alain Pécoud
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers. [PDF]

PLoS One
Kim TH, Memarzadeh S, Vahdatshariatpanahi S, Ostrzega N, Kang Y, Moatamed NA.   +5 more
europepmc   +1 more source

Effects of histamine and its receptor antagonists on peritoneal permeability

, 1988
Avshalom Shostak, Eva Chakrabarti, Przemyslaw Hirszel, John F. Maher   +3 more
openalex   +1 more source